Epilepsy Research
Volume 83, Issue 1 , Pages 1-43, January 2009

Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX)

  • Meir Bialer

      Affiliations

    • Department of Pharmaceutics, School of Pharmacy and David R. Bloom Centre for Pharmacy, Faculty of Medicine, Ein Karem, The Hebrew University of Jerusalem, 91120 Jerusalem, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 2 6758610; fax: +972 2 6757246.
    • ,
  • Svein I. Johannessen

      Affiliations

    • The National Center for Epilepsy, Sandvika, Division of Clinical Neuroscience, Rikshospitalet University Hospital, Oslo, Norway
    • ,
  • René H. Levy

      Affiliations

    • Department of Pharmaceutics and Neurological Surgery, University of Washington, Seattle, WA, USA
    • ,
  • Emilio Perucca

      Affiliations

    • Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, and Institute of Neurology IRCCS C. Mondino Foundation, Pavia, Italy
    • ,
  • Torbjörn Tomson

      Affiliations

    • Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
    • ,
  • H. Steve White

      Affiliations

    • Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA

Received 15 July 2008; received in revised form 7 September 2008; accepted 15 September 2008.

Summary 

The Ninth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT IX, took place in Sitges, Barcelona from the 15th to 19th of June 2008. Over 300 basic scientists, clinical pharmacologists and neurologists from 25 countries attended the conference, whose main themes included old and new AEDs in generalized epilepsies, novel formulations and routes of administration of AEDs, common targets and mechanisms of action of drugs for treating epilepsy and other central nervous system (CNS) disorders, and opportunities and perspectives in new AED discovery. Consistent with previous formats of this conference, a large part of the programme was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 1989. Unlike previous EILAT manuscripts, the current (EILAT IX) manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development. These include brivaracetam, carisbamate (RWJ-333369), 2-deoxy-d-glucose, eslicarbazepine acetate (BIA-2-093), ganaxolone, huperzine, JZP-4, lacosamide, NAX-5055, propylisopropylacetamide (PID), retigabine, T-2000, tonabersat, valrocemide and YKP-3089. The CNS efficacy of these compounds in anticonvulsant animal models as well as other disease model systems are presented in first and second tables and their proposed mechanisms of action are summarized in the third table.

Keywords: Antiepileptic drugs, Drug development, Epilepsy, Pharmacology, Clinical trials, Conference

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0920-1211(08)00261-1

doi:10.1016/j.eplepsyres.2008.09.005

Epilepsy Research
Volume 83, Issue 1 , Pages 1-43, January 2009

Article Tools

* Image Usage & Resolution